首页 > 最新文献

European Journal of Pediatrics最新文献

英文 中文
Unraveling cardiac anomalies in pediatric neurofibromatosis type 1: insights and implications. 揭示小儿1型神经纤维瘤病的心脏异常:见解和意义。
IF 2.6 3区 医学 Q1 PEDIATRICS Pub Date : 2026-01-15 DOI: 10.1007/s00431-025-06702-8
Sohier Yahia, Zahraa Abdelmoneim, Dina Ghozzy, Yahya Wahba, Hany M Abo-Haded

Neurofibromatosis type 1 (NF1) is an autosomal dominant syndrome caused by mutations in the NF1 gene. Although cardiac abnormalities have been observed in NF1, they are frequently overlooked due to a lack of routine cardiac surveillance. Myocardial strain imaging offers a sensitive and non-invasive method for detecting early subclinical myocardial dysfunction. This study aims to detect cardiac abnormalities in children with NF1 using conventional echocardiography, Doppler tissue imaging (DTI), and myocardial strain analysis. A case-control study was conducted on 38 asymptomatic children with clinically confirmed NF1 and 35 healthy, age- and sex-matched controls. All patients underwent ECG, conventional echocardiography, DTI, and two-dimensional speckle-tracking echocardiography. NF1 patients showed significantly decreased ejection fraction (p = 0.0009) and higher interventricular septal and posterior wall thickness during systole (p < 0.0001). DTI revealed reduced mitral systolic (Sm) and early diastolic (Em) velocities, longer isovolumic contraction and relaxation periods, and increased LV Tei index values (p < 0.0001), indicating combined systolic and diastolic dysfunction. Also, myocardial strain analysis in NF1 children revealed considerably lower peak systolic left ventricular global longitudinal strain (LVGLS) (p 0.0014), as well as lower peak systolic septal and lateral wall strain values (p 0.0046, 0.0027), respectively. Conclusion: Children with NF1 show early subclinical myocardial dysfunction, even when there is no hypertension or overt cardiac symptoms. These findings highlight the significance of frequent echocardiographic screening, including strain imaging, for the early diagnosis and longitudinal monitoring of heart function in NF1 children.  What is Known: • Neurofibromatosis type 1 (NF1) is a multisystem syndrome that can involve the cardiovascular system. • Previous studies showed hypertrophic cardiac changes in NF1 patients, but data in children, especially those without hypertension, are limited, as routine echocardiography is not involved in NF1 management. What is New: • Our study revealed early subclinical myocardial dysfunction in NF1 children without the presence of hypertension or overt cardiac symptoms. • This emphasizes the potential of myocardial strain imaging as a sensitive tool for early detection of myocardial dysfunction in NF1 children, thereby supporting the need for routine echocardiographic surveillance in these patients.

1型神经纤维瘤病(NF1)是由NF1基因突变引起的常染色体显性综合征。虽然在NF1中观察到心脏异常,但由于缺乏常规心脏监测,它们经常被忽视。心肌应变显像为检测早期亚临床心肌功能障碍提供了一种灵敏、无创的方法。本研究旨在通过常规超声心动图、多普勒组织成像(DTI)和心肌应变分析来检测NF1患儿的心脏异常。一项病例对照研究对38名临床确诊为NF1的无症状儿童和35名年龄和性别匹配的健康对照组进行了研究。所有患者均行心电图、常规超声心动图、DTI和二维斑点跟踪超声心动图检查。NF1患者在收缩期的射血分数明显降低(p = 0.0009),室间隔和后壁厚度增高(p = 0.0009)
{"title":"Unraveling cardiac anomalies in pediatric neurofibromatosis type 1: insights and implications.","authors":"Sohier Yahia, Zahraa Abdelmoneim, Dina Ghozzy, Yahya Wahba, Hany M Abo-Haded","doi":"10.1007/s00431-025-06702-8","DOIUrl":"10.1007/s00431-025-06702-8","url":null,"abstract":"<p><p>Neurofibromatosis type 1 (NF1) is an autosomal dominant syndrome caused by mutations in the NF1 gene. Although cardiac abnormalities have been observed in NF1, they are frequently overlooked due to a lack of routine cardiac surveillance. Myocardial strain imaging offers a sensitive and non-invasive method for detecting early subclinical myocardial dysfunction. This study aims to detect cardiac abnormalities in children with NF1 using conventional echocardiography, Doppler tissue imaging (DTI), and myocardial strain analysis. A case-control study was conducted on 38 asymptomatic children with clinically confirmed NF1 and 35 healthy, age- and sex-matched controls. All patients underwent ECG, conventional echocardiography, DTI, and two-dimensional speckle-tracking echocardiography. NF1 patients showed significantly decreased ejection fraction (p = 0.0009) and higher interventricular septal and posterior wall thickness during systole (p < 0.0001). DTI revealed reduced mitral systolic (Sm) and early diastolic (Em) velocities, longer isovolumic contraction and relaxation periods, and increased LV Tei index values (p < 0.0001), indicating combined systolic and diastolic dysfunction. Also, myocardial strain analysis in NF1 children revealed considerably lower peak systolic left ventricular global longitudinal strain (LVGLS) (p 0.0014), as well as lower peak systolic septal and lateral wall strain values (p 0.0046, 0.0027), respectively. Conclusion: Children with NF1 show early subclinical myocardial dysfunction, even when there is no hypertension or overt cardiac symptoms. These findings highlight the significance of frequent echocardiographic screening, including strain imaging, for the early diagnosis and longitudinal monitoring of heart function in NF1 children.  What is Known: • Neurofibromatosis type 1 (NF1) is a multisystem syndrome that can involve the cardiovascular system. • Previous studies showed hypertrophic cardiac changes in NF1 patients, but data in children, especially those without hypertension, are limited, as routine echocardiography is not involved in NF1 management. What is New: • Our study revealed early subclinical myocardial dysfunction in NF1 children without the presence of hypertension or overt cardiac symptoms. • This emphasizes the potential of myocardial strain imaging as a sensitive tool for early detection of myocardial dysfunction in NF1 children, thereby supporting the need for routine echocardiographic surveillance in these patients.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"79"},"PeriodicalIF":2.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12808207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intrapartum recognition and management of fetal inflammation. 产时胎儿炎症的识别和处理。
IF 2.6 3区 医学 Q1 PEDIATRICS Pub Date : 2026-01-15 DOI: 10.1007/s00431-025-06738-w
Elvira di Pasquo, Susana Pereira, Beatrice Valentini, Alessandra Familiari, Tullio Ghi

Intra-amniotic inflammation and infection are common intrapartum conditions at term and represent a major cause of fetal and neonatal morbidity independent of hypoxia. These conditions trigger the fetal inflammatory response syndrome (FIRS), characterized by systemic cytokine activation, cardiovascular dysfunction, impaired thermoregulation, and neuroinflammation, which substantially increase the risk of early-onset neonatal sepsis, encephalopathy, and long-term neurological injury. The coexistence of inflammation and intrapartum hypoxic stress markedly amplifies fetal brain vulnerability. During labor, fetal inflammation is associated with specific cardiotocographic patterns that may precede metabolic acidemia. Early signs include unexplained fetal tachycardia or a progressive rise in baseline heart rate, often without preceding decelerations. With progression, loss of accelerations, abnormalities of baseline variability-including increased, reduced, or atypical sinusoidal patterns-and absence of sleep-wake cycling become evident. Decelerations may develop secondary to inflammation-related placental dysfunction, altered umbilical blood flow, and abnormal uterine contractility.

Conclusion:  Prompt recognition of these intrapartum features allows early intervention through maternal temperature control, antibiotic therapy, and timely delivery when indicated. Early identification and management of fetal inflammation are essential to mitigate inflammation-mediated neonatal morbidity and adverse neurological outcomes.

What is known: • Intra-amniotic inflammation and infection during labor are common at term and are major contributors to fetal and neonatal morbidity. • Traditional intrapartum cardiotocography (CTG) interpretation is primarily focused on detecting hypoxia-related fetal compromise and may fail to recognize non-hypoxic inflammatory insults.

What is new: • Fetal exposure to intra-amniotic inflammation during labor can be identified antenatally through specific intrapartum cardiotocographic patterns, even in the absence of maternal clinical signs of infection. • The recognition of CTG features suggestive of fetal inflammation provides an opportunity for earlier intrapartum intervention, with potential to reduce neonatal sepsis, encephalopathy, and long-term neurological injury.

羊膜内炎症和感染是分娩时常见的情况,是胎儿和新生儿发病的主要原因,与缺氧无关。这些情况引发胎儿炎症反应综合征(FIRS),其特征是全身细胞因子激活、心血管功能障碍、体温调节受损和神经炎症,这大大增加了早发性新生儿败血症、脑病和长期神经损伤的风险。炎症和产时缺氧应激的共存明显增加了胎儿大脑的易感性。在分娩过程中,胎儿炎症与可能先于代谢性酸血症的特定心脏图模式相关。早期症状包括不明原因的胎儿心动过速或基线心率进行性升高,通常没有先前的减速。随着病情的发展,加速丧失,基线变异性异常(包括增加、减少或非典型正弦模式),睡眠-觉醒循环的缺失变得明显。减速可继发于炎症相关的胎盘功能障碍、脐血流量改变和子宫收缩性异常。结论:及时识别这些产时特征可以通过产妇体温控制、抗生素治疗和适时分娩进行早期干预。早期识别和处理胎儿炎症对于减轻炎症介导的新生儿发病率和不良神经系统预后至关重要。•分娩时羊膜内炎症和感染在足月很常见,是胎儿和新生儿发病率的主要原因。•传统的分娩时心脏造影(CTG)解释主要集中在检测与缺氧相关的胎儿损害,可能无法识别非缺氧炎症性损伤。新发现:•胎儿在分娩过程中暴露于羊膜内炎症,即使在没有母体感染临床体征的情况下,也可以通过特定的分娩时心电图模式进行产前识别。•识别提示胎儿炎症的CTG特征为早期分娩干预提供了机会,有可能减少新生儿败血症、脑病和长期神经损伤。
{"title":"Intrapartum recognition and management of fetal inflammation.","authors":"Elvira di Pasquo, Susana Pereira, Beatrice Valentini, Alessandra Familiari, Tullio Ghi","doi":"10.1007/s00431-025-06738-w","DOIUrl":"https://doi.org/10.1007/s00431-025-06738-w","url":null,"abstract":"<p><p>Intra-amniotic inflammation and infection are common intrapartum conditions at term and represent a major cause of fetal and neonatal morbidity independent of hypoxia. These conditions trigger the fetal inflammatory response syndrome (FIRS), characterized by systemic cytokine activation, cardiovascular dysfunction, impaired thermoregulation, and neuroinflammation, which substantially increase the risk of early-onset neonatal sepsis, encephalopathy, and long-term neurological injury. The coexistence of inflammation and intrapartum hypoxic stress markedly amplifies fetal brain vulnerability. During labor, fetal inflammation is associated with specific cardiotocographic patterns that may precede metabolic acidemia. Early signs include unexplained fetal tachycardia or a progressive rise in baseline heart rate, often without preceding decelerations. With progression, loss of accelerations, abnormalities of baseline variability-including increased, reduced, or atypical sinusoidal patterns-and absence of sleep-wake cycling become evident. Decelerations may develop secondary to inflammation-related placental dysfunction, altered umbilical blood flow, and abnormal uterine contractility.</p><p><strong>Conclusion: </strong> Prompt recognition of these intrapartum features allows early intervention through maternal temperature control, antibiotic therapy, and timely delivery when indicated. Early identification and management of fetal inflammation are essential to mitigate inflammation-mediated neonatal morbidity and adverse neurological outcomes.</p><p><strong>What is known: </strong>• Intra-amniotic inflammation and infection during labor are common at term and are major contributors to fetal and neonatal morbidity. • Traditional intrapartum cardiotocography (CTG) interpretation is primarily focused on detecting hypoxia-related fetal compromise and may fail to recognize non-hypoxic inflammatory insults.</p><p><strong>What is new: </strong>• Fetal exposure to intra-amniotic inflammation during labor can be identified antenatally through specific intrapartum cardiotocographic patterns, even in the absence of maternal clinical signs of infection. • The recognition of CTG features suggestive of fetal inflammation provides an opportunity for earlier intrapartum intervention, with potential to reduce neonatal sepsis, encephalopathy, and long-term neurological injury.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"81"},"PeriodicalIF":2.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145984791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validation of an accelerometer system for activity monitoring in children with functional disabilities. 用于功能障碍儿童活动监测的加速度计系统的验证。
IF 2.6 3区 医学 Q1 PEDIATRICS Pub Date : 2026-01-15 DOI: 10.1007/s00431-025-06679-4
Anna Stage, Emil Buch Fromberg, Peter Elsborg, Mette Røn Kristensen, Silje Mikkelsen, Mads Bølling, Mette Aadahl, Michelle Stahlhut

To assess the validity of the SENS motion® system (SENS) for measuring postures and movements in school-aged children with functional disabilities, using direct video observation as the criterion method. In this cross-sectional-study, 29 children (51.7% male, mean age 10.8 ± 2.9 years) from two special schools in Denmark participated. Each child wore a SENS device on the thigh while completing a standardized protocol of six categories: lying/sitting, standing, walking, running, cycling, and step count. All activities were video recorded. Video data were coded in 5-s epochs and aligned with SENS output. Agreement was assessed by comparing the observed time spent in each activity with the corresponding time estimated by SENS, expressed as mean values, standard deviations, mean differences, and percentage agreement. SENS showed excellent agreement for walking (93.2%) and lying/sitting (96.2%), good agreement for running (89.2%), and moderate agreement for standing (74.1%). Cycling was poorly detected, with only 6.4% agreement, as it was frequently misclassified as walking (50.8%) or lying/sitting (42.7%). Step counts were slightly overestimated by SENS (mean difference 7.2 steps). Overall, SENS tended to underestimate activity duration compared with the observation.

Conclusion:  SENS demonstrated excellent to good validity for detecting lying/sitting, walking, and acceptable validity for running in children with functional disabilities, but moderate validity for standing and limited validity for cycling. These findings indicate that SENS may be useful for monitoring several common postures and activities in this population, though further algorithm refinement and broader validation are needed, particularly for cycling and postural transitions.

What is known: • Children with disabilities engage in less dynamic postures and more lying/sitting time than their peers without disabilities. • Accelerometer systems are typically validated in healthy populations, limiting accuracy in children with disabilities.

What is new: • SENS shows excellent to good validity for lying/sitting, walking, and running in children with functional disabilities. • SENS performs poorly for cycling and moderately for standing, highlighting the need for algorithm refinement.

为了评估SENS运动®系统(SENS)测量学龄期功能障碍儿童姿势和运动的有效性,采用直接视频观察作为标准方法。在这项横断面研究中,来自丹麦两所特殊学校的29名儿童(51.7%为男性,平均年龄10.8±2.9岁)参与了研究。每个孩子都在大腿上佩戴SENS设备,同时完成六项标准化方案:躺/坐、站、走、跑、骑自行车和步数。所有的活动都被录像。视频数据以5秒为周期进行编码,并与SENS输出对齐。通过比较观察到的每项活动花费的时间与SENS估计的相应时间来评估一致性,以平均值、标准差、平均差异和一致性百分比表示。SENS对步行(93.2%)和躺/坐(96.2%)的一致性很好,对跑步(89.2%)的一致性很好,对站立(74.1%)的一致性中等。骑车很少被发现,只有6.4%的人同意,因为它经常被错误地归类为走路(50.8%)或躺着/坐着(42.7%)。SENS略微高估步数(平均差值为7.2步)。总的来说,与观察相比,SENS倾向于低估活动持续时间。结论:SENS检测功能障碍儿童躺/坐、行走的效度优异至良好,对跑步的效度尚可,但对站立的效度中等,对骑自行车的效度有限。这些发现表明,SENS可能对监测该人群的几种常见姿势和活动有用,尽管需要进一步的算法改进和更广泛的验证,特别是对于循环和姿势转换。已知情况:•残疾儿童比正常儿童的动态姿势更少,躺/坐的时间更多。•加速度计系统通常在健康人群中进行验证,限制了残疾儿童的准确性。新发现:•SENS在功能障碍儿童的躺/坐、行走和跑步方面表现出极好的有效性。•SENS在骑行时表现不佳,在站立时表现中等,这凸显了算法改进的必要性。
{"title":"Validation of an accelerometer system for activity monitoring in children with functional disabilities.","authors":"Anna Stage, Emil Buch Fromberg, Peter Elsborg, Mette Røn Kristensen, Silje Mikkelsen, Mads Bølling, Mette Aadahl, Michelle Stahlhut","doi":"10.1007/s00431-025-06679-4","DOIUrl":"10.1007/s00431-025-06679-4","url":null,"abstract":"<p><p>To assess the validity of the SENS motion® system (SENS) for measuring postures and movements in school-aged children with functional disabilities, using direct video observation as the criterion method. In this cross-sectional-study, 29 children (51.7% male, mean age 10.8 ± 2.9 years) from two special schools in Denmark participated. Each child wore a SENS device on the thigh while completing a standardized protocol of six categories: lying/sitting, standing, walking, running, cycling, and step count. All activities were video recorded. Video data were coded in 5-s epochs and aligned with SENS output. Agreement was assessed by comparing the observed time spent in each activity with the corresponding time estimated by SENS, expressed as mean values, standard deviations, mean differences, and percentage agreement. SENS showed excellent agreement for walking (93.2%) and lying/sitting (96.2%), good agreement for running (89.2%), and moderate agreement for standing (74.1%). Cycling was poorly detected, with only 6.4% agreement, as it was frequently misclassified as walking (50.8%) or lying/sitting (42.7%). Step counts were slightly overestimated by SENS (mean difference 7.2 steps). Overall, SENS tended to underestimate activity duration compared with the observation.</p><p><strong>Conclusion: </strong> SENS demonstrated excellent to good validity for detecting lying/sitting, walking, and acceptable validity for running in children with functional disabilities, but moderate validity for standing and limited validity for cycling. These findings indicate that SENS may be useful for monitoring several common postures and activities in this population, though further algorithm refinement and broader validation are needed, particularly for cycling and postural transitions.</p><p><strong>What is known: </strong>• Children with disabilities engage in less dynamic postures and more lying/sitting time than their peers without disabilities. • Accelerometer systems are typically validated in healthy populations, limiting accuracy in children with disabilities.</p><p><strong>What is new: </strong>• SENS shows excellent to good validity for lying/sitting, walking, and running in children with functional disabilities. • SENS performs poorly for cycling and moderately for standing, highlighting the need for algorithm refinement.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"78"},"PeriodicalIF":2.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12808203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145984728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PODiaCarD: a prototype of a digital twin platform for the management of pediatric obesity and related cardiometabolic complications. PODiaCarD:用于管理儿童肥胖和相关心脏代谢并发症的数字双胞胎平台的原型。
IF 2.6 3区 医学 Q1 PEDIATRICS Pub Date : 2026-01-14 DOI: 10.1007/s00431-025-06708-2
Valeria Calcaterra, Umberto Ciriello, Samuele Medici, Valter Pagani, Cristina Campoy, Lucia Labati, Virginia Rossi, Mireia Escudero-Marin, Matteo Vandoni, Camilo Corbellini, Elvira Verduci, Luca Marin, Rocio Bonillo-Leon, Khatija Bahdur, Alessandro Gatti, Giulia Fiore, Vittoria Carnevale Pellino, Savina Mannarino, Gianvincenzo Zuccotti
<p><p>Childhood obesity is the main driver of early metabolic risk, predisposing to cardiovascular disease (CVD) and type 2 diabetes (T2D), which cause millions of deaths worldwide. Their progression is influenced by biological, behavioral, and environmental factors. Digital Twin Systems (DTS) offer innovative ways to monitor and predict cardiometabolic risk. This work presents a prototype digital twin platform called PODiaCarD designed for managing pediatric obesity and related cardiometabolic complications. The system integrates clinical, anthropometric, and lifestyle data with machine learning to estimate outcomes in youth. Built on a three-layer architecture (frontend, backend, predictive engine), PODiaCarD ensures scalability, observability, and reproducibility while enabling continuous model improvement. Models, trained on the PODiaCar project dataset (n = 552, 12.2 ± 2.9 years) with cross-validation and target-specific algorithms, predict eight key metabolic outcomes. The infrastructure follows privacy-by-design and GDPR standards, ensuring security, auditability, and clinical compliance. PODiaCarD achieved excellent performance for TyG index (F1 = 0.975 ± 0.014, random forest) and solid results for HbA1C (F1 = 0.844 ± 0.028, random forest). Moderate accuracy was observed for HOMA (F1 = 0.670 ± 0.070, Gradient Boosting). In contrast, models for blood pressure (R<sup>2</sup> = 0.05-0.21; F1 = 0.446 ± 0.045) and glycemia (F1 = 0.113 ± 0.113) showed poor predictive capacity, while insulin regression (R<sup>2</sup> = 0.211) remained limited, highlighting the need for richer datasets.</p><p><strong>Conclusions: </strong> PODiaCarD is a promising tool for managing pediatric obesity and complications. It integrates clinical, anthropometric, and behavioral data with ML-based models to support pediatricians in early risk detection, dynamic monitoring, and personalized prevention. Its federated design allows continuous dataset growth and improved predictive performance, strengthening its role in pediatric cardiometabolic care.</p><p><strong>What is known: </strong>• Pediatric obesity is a major early driver of cardiometabolic risk; body mass index, waist circumference, and lipid profile are key indicators of insulin resistance, type 2 diabetes, and cardiovascular diseases. Existing pediatric predictive models are often static and limited in longitudinal integration. • Digital Twin Systems enable dynamic monitoring and "what-if" simulations in healthcare, but cardiometabolic applications in pediatric populations remain scarce and insufficiently validated.</p><p><strong>What is new: </strong>• PODiaCarD introduces a federated pediatric digital twin that integrates clinical, anthropometric, and lifestyle data with machine learning to dynamically update individual cardiometabolic risk profiles over time. • The platform achieves strong performance for insulin resistance surrogates and HbA1c prediction, provides explainable AI outputs, ensures privacy-by-
儿童肥胖是早期代谢风险的主要驱动因素,易患心血管疾病(CVD)和2型糖尿病(T2D),这两种疾病在全世界造成数百万人死亡。它们的发展受生物、行为和环境因素的影响。数字孪生系统(DTS)提供了监测和预测心脏代谢风险的创新方法。这项工作提出了一个名为PODiaCarD的原型数字双胞胎平台,旨在管理儿童肥胖和相关的心脏代谢并发症。该系统将临床、人体测量和生活方式数据与机器学习相结合,以估计青少年的结果。PODiaCarD构建在三层架构(前端、后端、预测引擎)上,确保了可伸缩性、可观察性和再现性,同时支持持续的模型改进。在PODiaCar项目数据集(n = 552, 12.2±2.9年)上进行交叉验证和目标特异性算法训练的模型预测了8个关键代谢结局。该基础设施遵循隐私设计和GDPR标准,确保安全性、可审计性和临床合规性。PODiaCarD在TyG指标(F1 = 0.975±0.014,随机森林)和HbA1C指标(F1 = 0.844±0.028,随机森林)上表现优异。HOMA准确度中等(F1 = 0.670±0.070,Gradient Boosting)。相比之下,血压(R2 = 0.05-0.21; F1 = 0.446±0.045)和血糖(F1 = 0.113±0.113)模型的预测能力较差,而胰岛素回归(R2 = 0.211)仍然有限,需要更丰富的数据集。结论:PODiaCarD是一种很有前途的治疗儿童肥胖及其并发症的工具。它将临床、人体测量和行为数据与基于ml的模型相结合,以支持儿科医生进行早期风险检测、动态监测和个性化预防。其联合设计允许持续的数据集增长和改进的预测性能,加强其在儿科心脏代谢护理中的作用。了解情况:•儿童肥胖是心脏代谢风险的主要早期驱动因素;体重指数、腰围和血脂是胰岛素抵抗、2型糖尿病和心血管疾病的关键指标。现有的儿科预测模型往往是静态的,在纵向整合方面受到限制。•Digital Twin Systems能够在医疗保健领域实现动态监测和“假设”模拟,但在儿科人群中的心脏代谢应用仍然很少,而且还没有得到充分验证。创新点:•PODiaCarD引入了一个联邦儿科数字双胞胎,将临床、人体测量和生活方式数据与机器学习相结合,随着时间的推移动态更新个体心脏代谢风险概况。•该平台在胰岛素抵抗替代物和糖化血红蛋白预测方面表现出色,提供可解释的人工智能输出,确保隐私设计,并支持可扩展的多中心个性化预防策略。
{"title":"PODiaCarD: a prototype of a digital twin platform for the management of pediatric obesity and related cardiometabolic complications.","authors":"Valeria Calcaterra, Umberto Ciriello, Samuele Medici, Valter Pagani, Cristina Campoy, Lucia Labati, Virginia Rossi, Mireia Escudero-Marin, Matteo Vandoni, Camilo Corbellini, Elvira Verduci, Luca Marin, Rocio Bonillo-Leon, Khatija Bahdur, Alessandro Gatti, Giulia Fiore, Vittoria Carnevale Pellino, Savina Mannarino, Gianvincenzo Zuccotti","doi":"10.1007/s00431-025-06708-2","DOIUrl":"https://doi.org/10.1007/s00431-025-06708-2","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Childhood obesity is the main driver of early metabolic risk, predisposing to cardiovascular disease (CVD) and type 2 diabetes (T2D), which cause millions of deaths worldwide. Their progression is influenced by biological, behavioral, and environmental factors. Digital Twin Systems (DTS) offer innovative ways to monitor and predict cardiometabolic risk. This work presents a prototype digital twin platform called PODiaCarD designed for managing pediatric obesity and related cardiometabolic complications. The system integrates clinical, anthropometric, and lifestyle data with machine learning to estimate outcomes in youth. Built on a three-layer architecture (frontend, backend, predictive engine), PODiaCarD ensures scalability, observability, and reproducibility while enabling continuous model improvement. Models, trained on the PODiaCar project dataset (n = 552, 12.2 ± 2.9 years) with cross-validation and target-specific algorithms, predict eight key metabolic outcomes. The infrastructure follows privacy-by-design and GDPR standards, ensuring security, auditability, and clinical compliance. PODiaCarD achieved excellent performance for TyG index (F1 = 0.975 ± 0.014, random forest) and solid results for HbA1C (F1 = 0.844 ± 0.028, random forest). Moderate accuracy was observed for HOMA (F1 = 0.670 ± 0.070, Gradient Boosting). In contrast, models for blood pressure (R&lt;sup&gt;2&lt;/sup&gt; = 0.05-0.21; F1 = 0.446 ± 0.045) and glycemia (F1 = 0.113 ± 0.113) showed poor predictive capacity, while insulin regression (R&lt;sup&gt;2&lt;/sup&gt; = 0.211) remained limited, highlighting the need for richer datasets.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt; PODiaCarD is a promising tool for managing pediatric obesity and complications. It integrates clinical, anthropometric, and behavioral data with ML-based models to support pediatricians in early risk detection, dynamic monitoring, and personalized prevention. Its federated design allows continuous dataset growth and improved predictive performance, strengthening its role in pediatric cardiometabolic care.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;What is known: &lt;/strong&gt;• Pediatric obesity is a major early driver of cardiometabolic risk; body mass index, waist circumference, and lipid profile are key indicators of insulin resistance, type 2 diabetes, and cardiovascular diseases. Existing pediatric predictive models are often static and limited in longitudinal integration. • Digital Twin Systems enable dynamic monitoring and \"what-if\" simulations in healthcare, but cardiometabolic applications in pediatric populations remain scarce and insufficiently validated.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;What is new: &lt;/strong&gt;• PODiaCarD introduces a federated pediatric digital twin that integrates clinical, anthropometric, and lifestyle data with machine learning to dynamically update individual cardiometabolic risk profiles over time. • The platform achieves strong performance for insulin resistance surrogates and HbA1c prediction, provides explainable AI outputs, ensures privacy-by-","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"77"},"PeriodicalIF":2.6,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibiotics in the first week of life and the association with atopic diseases at ages 9-12: a prospective cohort study. 9-12岁儿童出生后第一周使用抗生素与特应性疾病的关系:一项前瞻性队列研究
IF 2.6 3区 医学 Q1 PEDIATRICS Pub Date : 2026-01-14 DOI: 10.1007/s00431-025-06725-1
Nora C Carpay, Kim Kamphorst, Arine M Vlieger, Ruurd M van Elburg

Dysbiosis in early life has been associated with the development of atopic diseases. In the INCA study, antibiotic treatment in the first week of life was associated with wheezing at 1 year and food allergies at 4-6 years. This follow-up study investigates whether these associations persist at age 9-12, and whether new associations with other atopic diseases have developed. The INCA cohort consisted of 436 children included in 2012-2015 to investigate the long-term effects of antibiotic treatment in the first week of life. Term-born infants from four Dutch hospitals were included, of which 151 received intravenous antibiotics in their first week of life due to suspected early-onset sepsis (AB+), and 285 were unexposed infants (AB-). In the 9-12-year follow-up study, parents and children filled out questionnaires on atopic diseases. Furthermore, general practitioners' diagnoses were collected. The follow-up questionnaire was completed by 314 participants. Parental-reported and test-confirmed food allergies were more prevalent in AB+ children compared to AB- (unadjusted odds ratio (OR) 3.52, 95% confidence interval (CI) 1.50-8.25 and OR 6.6, 95% CI 1.3-32, respectively). However, no significant differences existed between AB+ and AB- in the incidence of asthma (OR 0.73, 95% CI 0.25-2.1) or inhalant allergies (OR 1.03, 95% CI 0.554-1.91). The "any allergy" diagnosis by general practitioners was more prevalent in AB+ than AB- (OR 3.0, 95% CI 1.2-7.6).

Conclusions:  Antibiotic treatment in the first week of life is associated with food allergies at ages 9-12, but not with asthma, inhalant allergies, or eczema.

What is known: • Correlations have been observed between early life antibiotics exposure (< 2 years of age) and the development of atopic diseases such as asthma, eczema, and allergies. • Antibiotics exposure specifically in the first week of life has been associated with an increased risk of wheezing at age 1 and food allergies at ages 4-6.

What is new: • Antibiotics in the first week of life are still associated with food allergies at ages 9-12, but not with airway atopy (asthma, hay fever, or inhalant allergies). • The results of this study suggest that there may be different mechanisms involved in the development of food vs. inhalant allergies, and further research is needed to determine how these diseases develop and how to prevent this.

生命早期的生态失调与特应性疾病的发展有关。在INCA的研究中,出生后第一周的抗生素治疗与1岁时的喘息和4-6岁时的食物过敏有关。这项后续研究调查了这些关联是否在9-12岁时持续存在,以及是否与其他特应性疾病产生了新的关联。INCA队列包括2012-2015年纳入的436名儿童,以调查生命第一周抗生素治疗的长期影响。研究纳入了来自荷兰四家医院的足月婴儿,其中151名因疑似早发性败血症(AB+)而在出生后第一周接受静脉注射抗生素,285名未接触抗生素的婴儿(AB-)。在9-12年的随访研究中,父母和孩子填写了有关特应性疾病的问卷。此外,收集全科医生的诊断。314名参与者完成了随访问卷。父母报告和测试证实的食物过敏在AB+儿童中比AB-儿童更普遍(未调整比值比(OR) 3.52, 95%置信区间(CI) 1.50-8.25, OR 6.6, 95% CI 1.3-32)。然而,AB+和AB-在哮喘(OR 0.73, 95% CI 0.25-2.1)或吸入性过敏(OR 1.03, 95% CI 0.554-1.91)的发生率上没有显著差异。全科医生的“任何过敏”诊断在AB+中比AB-更普遍(OR 3.0, 95% CI 1.2-7.6)。结论:出生第一周的抗生素治疗与9-12岁的食物过敏有关,但与哮喘、吸入性过敏或湿疹无关。•观察到生命早期抗生素暴露之间的相关性(新发现:•生命第一周的抗生素仍然与9-12岁的食物过敏有关,但与气道特应性(哮喘,花粉热或吸入性过敏)无关。•这项研究的结果表明,食物过敏和吸入物过敏的发展可能有不同的机制,需要进一步的研究来确定这些疾病是如何发展的,以及如何预防。
{"title":"Antibiotics in the first week of life and the association with atopic diseases at ages 9-12: a prospective cohort study.","authors":"Nora C Carpay, Kim Kamphorst, Arine M Vlieger, Ruurd M van Elburg","doi":"10.1007/s00431-025-06725-1","DOIUrl":"10.1007/s00431-025-06725-1","url":null,"abstract":"<p><p>Dysbiosis in early life has been associated with the development of atopic diseases. In the INCA study, antibiotic treatment in the first week of life was associated with wheezing at 1 year and food allergies at 4-6 years. This follow-up study investigates whether these associations persist at age 9-12, and whether new associations with other atopic diseases have developed. The INCA cohort consisted of 436 children included in 2012-2015 to investigate the long-term effects of antibiotic treatment in the first week of life. Term-born infants from four Dutch hospitals were included, of which 151 received intravenous antibiotics in their first week of life due to suspected early-onset sepsis (AB+), and 285 were unexposed infants (AB-). In the 9-12-year follow-up study, parents and children filled out questionnaires on atopic diseases. Furthermore, general practitioners' diagnoses were collected. The follow-up questionnaire was completed by 314 participants. Parental-reported and test-confirmed food allergies were more prevalent in AB+ children compared to AB- (unadjusted odds ratio (OR) 3.52, 95% confidence interval (CI) 1.50-8.25 and OR 6.6, 95% CI 1.3-32, respectively). However, no significant differences existed between AB+ and AB- in the incidence of asthma (OR 0.73, 95% CI 0.25-2.1) or inhalant allergies (OR 1.03, 95% CI 0.554-1.91). The \"any allergy\" diagnosis by general practitioners was more prevalent in AB+ than AB- (OR 3.0, 95% CI 1.2-7.6).</p><p><strong>Conclusions: </strong> Antibiotic treatment in the first week of life is associated with food allergies at ages 9-12, but not with asthma, inhalant allergies, or eczema.</p><p><strong>What is known: </strong>• Correlations have been observed between early life antibiotics exposure (< 2 years of age) and the development of atopic diseases such as asthma, eczema, and allergies. • Antibiotics exposure specifically in the first week of life has been associated with an increased risk of wheezing at age 1 and food allergies at ages 4-6.</p><p><strong>What is new: </strong>• Antibiotics in the first week of life are still associated with food allergies at ages 9-12, but not with airway atopy (asthma, hay fever, or inhalant allergies). • The results of this study suggest that there may be different mechanisms involved in the development of food vs. inhalant allergies, and further research is needed to determine how these diseases develop and how to prevent this.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"76"},"PeriodicalIF":2.6,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Behavioural determinants of the use of pain-reducing interventions-a survey among professionals who vaccinate children. 使用减轻疼痛干预措施的行为决定因素——对为儿童接种疫苗的专业人员的调查。
IF 2.6 3区 医学 Q1 PEDIATRICS Pub Date : 2026-01-13 DOI: 10.1007/s00431-025-06740-2
Bianca van Vreeswijk, Sijmen A Reijneveld, Netty Bos-Veneman

Childhood vaccination is a very effective public health intervention. Fear of pain during vaccination reduces vaccine willingness and can be addressed by interventions. We aimed to identify behavioural determinants of the use of pain-reducing interventions by Preventive Child Healthcare (PCH) physicians and nurses and the associations of sociodemographic characteristics with these behavioural determinants. We invited all PCH professionals of one municipal health service (Groningen, the Netherlands; n = 180) to fill in an online questionnaire on behavioural determinants of the use of pain-reducing interventions, based on the ASE (Attitude-Social influence-self-Efficacy) model of behaviour. We evaluated the associations of their background characteristics with their responses using logistic regression analyses. Of the 83 PCH professionals, 95% considered it important to reduce pain during vaccination, 90% intended to liaise with children and parents about pain mitigation, and 85% reported a high self-efficacy regarding the use of pain-reducing interventions. Lack of time and knowledge about pain reduction, and difficulties in the use of pain mitigation were negatively associated with the use of pain-reducing interventions. Nurses were more likely than physicians to liaise with children and parents about pain mitigation during vaccination (odds ratio, 95% confidence interval 8.86, 1.62 to 48.4) and believe they are competent to mitigate pain during vaccination (6.27, 1.65 to 23.9).

Conclusion:  Most PCH professionals acknowledge the importance of reducing pain during vaccination but experience various barriers in the use of pain-reducing interventions. Education of professionals might contribute to the adherence to guidelines regarding pain reduction.

What is known: • Childhood vaccination is a very effective public health intervention. • Fear of pain during vaccination reduces vaccine willingness and can be addressed by interventions.

What is new: • Most Preventive Child Healthcare physicians and nurses acknowledge the importance of reducing pain during vaccination but experience various barriers in the use of pain-reducing interventions. • Education of professionals might contribute to the adherence to guidelines regarding pain reduction.

儿童接种疫苗是一项非常有效的公共卫生干预措施。接种疫苗时对疼痛的恐惧会降低接种意愿,可通过干预措施加以解决。我们旨在确定预防儿童保健(PCH)医生和护士使用减轻疼痛干预措施的行为决定因素,以及社会人口特征与这些行为决定因素的关联。我们邀请了一个市政卫生服务机构(荷兰格罗宁根;n = 180)的所有PCH专业人员填写了一份基于ASE(态度-社会影响-自我效能)行为模型的关于使用减轻疼痛干预措施的行为决定因素的在线问卷。我们使用逻辑回归分析评估了他们的背景特征与他们的反应之间的关联。在83名PCH专业人员中,95%的人认为在接种疫苗期间减轻疼痛很重要,90%的人打算就减轻疼痛与儿童和家长保持联系,85%的人报告说,他们对使用减轻疼痛的干预措施有很高的自我效能感。缺乏关于减轻疼痛的时间和知识,以及在使用减轻疼痛方面的困难与使用减轻疼痛干预措施呈负相关。护士比医生更有可能与儿童和家长就疫苗接种期间减轻疼痛进行沟通(优势比,95%置信区间为8.86,1.62至48.4),并相信自己有能力减轻疫苗接种期间的疼痛(优势比为6.27,95%置信区间为1.65至23.9)。结论:大多数PCH专业人员承认在疫苗接种期间减轻疼痛的重要性,但在使用减轻疼痛的干预措施方面遇到各种障碍。专业人员的教育可能有助于遵守有关减轻疼痛的指导方针。已知情况:•儿童接种疫苗是一项非常有效的公共卫生干预措施。•接种疫苗时害怕疼痛会降低接种意愿,可通过干预措施加以解决。•大多数预防性儿童保健医生和护士承认在接种疫苗期间减少疼痛的重要性,但在使用减轻疼痛的干预措施方面遇到各种障碍。•专业人员的教育可能有助于遵守有关减轻疼痛的指导方针。
{"title":"Behavioural determinants of the use of pain-reducing interventions-a survey among professionals who vaccinate children.","authors":"Bianca van Vreeswijk, Sijmen A Reijneveld, Netty Bos-Veneman","doi":"10.1007/s00431-025-06740-2","DOIUrl":"10.1007/s00431-025-06740-2","url":null,"abstract":"<p><p>Childhood vaccination is a very effective public health intervention. Fear of pain during vaccination reduces vaccine willingness and can be addressed by interventions. We aimed to identify behavioural determinants of the use of pain-reducing interventions by Preventive Child Healthcare (PCH) physicians and nurses and the associations of sociodemographic characteristics with these behavioural determinants. We invited all PCH professionals of one municipal health service (Groningen, the Netherlands; n = 180) to fill in an online questionnaire on behavioural determinants of the use of pain-reducing interventions, based on the ASE (Attitude-Social influence-self-Efficacy) model of behaviour. We evaluated the associations of their background characteristics with their responses using logistic regression analyses. Of the 83 PCH professionals, 95% considered it important to reduce pain during vaccination, 90% intended to liaise with children and parents about pain mitigation, and 85% reported a high self-efficacy regarding the use of pain-reducing interventions. Lack of time and knowledge about pain reduction, and difficulties in the use of pain mitigation were negatively associated with the use of pain-reducing interventions. Nurses were more likely than physicians to liaise with children and parents about pain mitigation during vaccination (odds ratio, 95% confidence interval 8.86, 1.62 to 48.4) and believe they are competent to mitigate pain during vaccination (6.27, 1.65 to 23.9).</p><p><strong>Conclusion: </strong> Most PCH professionals acknowledge the importance of reducing pain during vaccination but experience various barriers in the use of pain-reducing interventions. Education of professionals might contribute to the adherence to guidelines regarding pain reduction.</p><p><strong>What is known: </strong>• Childhood vaccination is a very effective public health intervention. • Fear of pain during vaccination reduces vaccine willingness and can be addressed by interventions.</p><p><strong>What is new: </strong>• Most Preventive Child Healthcare physicians and nurses acknowledge the importance of reducing pain during vaccination but experience various barriers in the use of pain-reducing interventions. • Education of professionals might contribute to the adherence to guidelines regarding pain reduction.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"74"},"PeriodicalIF":2.6,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12795855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of an explainable prediction model for the risk of moderate-to-severe obstructive sleep apnea in children. 建立可解释的儿童中度至重度阻塞性睡眠呼吸暂停风险预测模型。
IF 2.6 3区 医学 Q1 PEDIATRICS Pub Date : 2026-01-13 DOI: 10.1007/s00431-025-06731-3
Fuzhi Lin, Yufei Peng, Xiaowei Chen, Wei Wu, Yong Fu

Early identification of children at high risk for moderate-to-severe obstructive sleep apnea (OSA) is crucial for timely intervention, yet is often hindered by limited access to polysomnography (PSG). We aimed to develop an interpretable clinical prediction model using easily obtainable clinical and inflammatory biomarkers to distinguish moderate-to-severe from mild pediatric OSA. We conducted a retrospective study of 164 children diagnosed with OSA by PSG. From multiple biomarkers and clinical variables, least absolute shrinkage and selection operator (LASSO) regression was employed to select the most predictive features. A multivariable logistic regression model was built and presented as an interpretable nomogram. Model performance was evaluated via bootstrap validation assessing discrimination, calibration, and clinical utility. The LASSO algorithm identified eight core predictors: female, tonsil size grades 3 and 4, adenoid-to-nasopharynx ratio (A/N ratio), IgE, IL-4, IL-6, and IL-10. The final model demonstrated robust performance, with a bootstrap-corrected AUC of 0.763 (95%CI 0.690-0.836). Decision curve analysis confirmed the model's clinical utility.

Conclusion:  We developed an explainable nomogram that integrates upper airway anatomy, allergic, sex, and specific inflammatory cytokines. This tool provides clinicians with a practical, non-invasive method for individualized risk assessment, facilitating the identification of children with moderate-to-severe OSA who may benefit from prioritized diagnosis and intervention.

What is known: • Polysomnography(PSG) is the gold standard for diagnosing pediatric obstructive sleep apnea (OSA) but has limited accessibility, hindering the early identification of children at risk for moderate-to-severe disease.

What is new: • We developed an explainable nomogram that integrates sex, tonsil size, adenoid hypertrophy, allergy (IgE), and specific inflammatory cytokines (IL-4, IL-6, IL-10) to provide a practical, noninvasive tool for individualized risk assessment of moderate-to-severe OSA in children.

早期识别中度至重度阻塞性睡眠呼吸暂停(OSA)高风险儿童对于及时干预至关重要,但往往受到多导睡眠图(PSG)有限的阻碍。我们的目的是建立一个可解释的临床预测模型,使用易于获得的临床和炎症生物标志物来区分中度至重度和轻度儿科OSA。我们对164名经PSG诊断为OSA的儿童进行了回顾性研究。从多个生物标志物和临床变量中,采用最小绝对收缩和选择算子(LASSO)回归来选择最具预测性的特征。建立了一个多变量逻辑回归模型,并将其表示为可解释的nomogram。通过自举验证评估鉴别、校准和临床效用来评估模型的性能。LASSO算法确定了8个核心预测指标:女性、扁桃体大小等级3级和4级、腺样体与鼻咽比率(A/N比率)、IgE、IL-4、IL-6和IL-10。最终模型表现出稳健的性能,bootstrap校正的AUC为0.763 (95%CI为0.690-0.836)。决策曲线分析证实了该模型的临床实用性。结论:我们开发了一个可解释的nomogram,整合了上呼吸道解剖、过敏、性别和特异性炎症细胞因子。该工具为临床医生提供了一种实用的、非侵入性的个体化风险评估方法,有助于识别中重度阻塞性睡眠呼吸暂停儿童,这些儿童可能受益于优先诊断和干预。•多导睡眠图(PSG)是诊断儿童阻塞性睡眠呼吸暂停(OSA)的金标准,但其可及性有限,阻碍了对有中度至重度疾病风险的儿童的早期识别。新发现:•我们开发了一种可解释的nomogram,将性别、扁桃体大小、腺样体肥大、过敏(IgE)和特异性炎症细胞因子(IL-4、IL-6、IL-10)整合在一起,为儿童中重度OSA的个体化风险评估提供了一种实用的、无创的工具。
{"title":"Development of an explainable prediction model for the risk of moderate-to-severe obstructive sleep apnea in children.","authors":"Fuzhi Lin, Yufei Peng, Xiaowei Chen, Wei Wu, Yong Fu","doi":"10.1007/s00431-025-06731-3","DOIUrl":"https://doi.org/10.1007/s00431-025-06731-3","url":null,"abstract":"<p><p>Early identification of children at high risk for moderate-to-severe obstructive sleep apnea (OSA) is crucial for timely intervention, yet is often hindered by limited access to polysomnography (PSG). We aimed to develop an interpretable clinical prediction model using easily obtainable clinical and inflammatory biomarkers to distinguish moderate-to-severe from mild pediatric OSA. We conducted a retrospective study of 164 children diagnosed with OSA by PSG. From multiple biomarkers and clinical variables, least absolute shrinkage and selection operator (LASSO) regression was employed to select the most predictive features. A multivariable logistic regression model was built and presented as an interpretable nomogram. Model performance was evaluated via bootstrap validation assessing discrimination, calibration, and clinical utility. The LASSO algorithm identified eight core predictors: female, tonsil size grades 3 and 4, adenoid-to-nasopharynx ratio (A/N ratio), IgE, IL-4, IL-6, and IL-10. The final model demonstrated robust performance, with a bootstrap-corrected AUC of 0.763 (95%CI 0.690-0.836). Decision curve analysis confirmed the model's clinical utility.</p><p><strong>Conclusion: </strong> We developed an explainable nomogram that integrates upper airway anatomy, allergic, sex, and specific inflammatory cytokines. This tool provides clinicians with a practical, non-invasive method for individualized risk assessment, facilitating the identification of children with moderate-to-severe OSA who may benefit from prioritized diagnosis and intervention.</p><p><strong>What is known: </strong>• Polysomnography(PSG) is the gold standard for diagnosing pediatric obstructive sleep apnea (OSA) but has limited accessibility, hindering the early identification of children at risk for moderate-to-severe disease.</p><p><strong>What is new: </strong>• We developed an explainable nomogram that integrates sex, tonsil size, adenoid hypertrophy, allergy (IgE), and specific inflammatory cytokines (IL-4, IL-6, IL-10) to provide a practical, noninvasive tool for individualized risk assessment of moderate-to-severe OSA in children.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"75"},"PeriodicalIF":2.6,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short- and long-term outcomes of binocular gaming versus patching in childhood amblyopia: a systematic review and meta-analysis. 儿童弱视的短期和长期结果:一项系统回顾和荟萃分析。
IF 2.6 3区 医学 Q1 PEDIATRICS Pub Date : 2026-01-12 DOI: 10.1007/s00431-025-06728-y
Luksanaporn Krungkraipetch, Dutdao Supajitgulchai, Angkhana Assawaboonyadech, Warisanan Puranawit, Kitti Krungkraipetch

The aim of this study is to systematically compare binocular gaming with conventional occlusion therapy for visual acuity improvement in childhood amblyopia. We conducted a systematic review and meta-analysis according to PRISMA 2020 guidelines (PROSPERO CRD420251080735). PubMed, Scopus, Cochrane Library, and Google Scholar were searched through June 2025 for randomized controlled trials in children aged 3-18 years with unilateral amblyopia. The primary outcome was best-corrected visual acuity improvement, expressed as standardized mean difference (SMD). A random-effects model was applied with subgroup analyses by treatment duration, sample size, and patient characteristics. Nine RCTs, including 986 children, met the inclusion criteria. Pooled analysis showed no significant difference between binocular gaming and patching (SMD 0.05, 95% CI - 0.2 to 0.3, p = 0.68) with substantial heterogeneity (I2 = 65%). Subgroup analyses revealed time-dependent effects: short-duration trials (≤ 6 weeks) favored binocular gaming (SMD 0.35, 95% CI 0.05-0.65, p = 0.02), medium-duration trials (8-12 weeks) showed no significant benefit, while long-duration trials (> 12 weeks) favored patching (SMD - 0.47, 95% CI - 0.72 to - 0.22, p < 0.001). Larger, high-quality trials consistently supported patching. Publication bias analysis indicated small-study effects, with trim-and-fill suggesting the true effect may favor patching (adjusted SMD - 0.15).

Conclusion: Binocular gaming may provide short-term benefits, but robust evidence indicates patching is superior for long-term outcomes. After adequate refractive correction, conventional occlusion therapy remains the recommended first-line active treatment for amblyopia. Binocular gaming may be considered as an adjunct or alternative for children who are unable to comply with patching.

What is known: • Patching is an effective standard treatment for childhood amblyopia. • Evidence for binocular gaming compared with patching has been inconsistent.

What is new: • Binocular gaming shows short-term benefit, but patching is superior long term. • High-quality trials support patching as first-line; gaming may be an adjunct.

本研究的目的是系统地比较双目游戏与常规遮挡治疗对儿童弱视视力改善的影响。我们根据PRISMA 2020指南(PROSPERO CRD420251080735)进行了系统评价和荟萃分析。PubMed、Scopus、Cochrane Library和谷歌Scholar检索了截至2025年6月的3-18岁单侧弱视儿童的随机对照试验。主要结果是最佳矫正视力改善,用标准化平均差(SMD)表示。采用随机效应模型,根据治疗时间、样本量和患者特征进行亚组分析。9项随机对照试验,包括986名儿童,符合纳入标准。综合分析显示,双目游戏和打补丁之间无显著差异(SMD 0.05, 95% CI - 0.2 ~ 0.3, p = 0.68),存在显著异质性(I2 = 65%)。亚组分析揭示了时间依赖性效应:短时间试验(≤6周)有利于双目游戏(SMD = 0.35, 95% CI = 0.05-0.65, p = 0.02),中时间试验(8-12周)没有明显的益处,而长时间试验(bb0 12周)有利于补片(SMD = 0.47, 95% CI = 0.72 - 0.22, p)。结论:双目游戏可能提供短期益处,但有力的证据表明补片对长期结果更有利。在充分的屈光矫正后,传统的遮挡治疗仍然是弱视推荐的一线积极治疗方法。双眼游戏可以被认为是一个辅助或替代儿童谁不能遵守补丁。已知情况:•贴片是儿童弱视的有效标准治疗方法。•与打补丁相比,双目游戏的证据并不一致。创新点:•双目游戏显示出短期收益,但补丁更具有长期优势。•高质量的试验支持打补丁作为一线;游戏可能是一种辅助手段。
{"title":"Short- and long-term outcomes of binocular gaming versus patching in childhood amblyopia: a systematic review and meta-analysis.","authors":"Luksanaporn Krungkraipetch, Dutdao Supajitgulchai, Angkhana Assawaboonyadech, Warisanan Puranawit, Kitti Krungkraipetch","doi":"10.1007/s00431-025-06728-y","DOIUrl":"10.1007/s00431-025-06728-y","url":null,"abstract":"<p><p>The aim of this study is to systematically compare binocular gaming with conventional occlusion therapy for visual acuity improvement in childhood amblyopia. We conducted a systematic review and meta-analysis according to PRISMA 2020 guidelines (PROSPERO CRD420251080735). PubMed, Scopus, Cochrane Library, and Google Scholar were searched through June 2025 for randomized controlled trials in children aged 3-18 years with unilateral amblyopia. The primary outcome was best-corrected visual acuity improvement, expressed as standardized mean difference (SMD). A random-effects model was applied with subgroup analyses by treatment duration, sample size, and patient characteristics. Nine RCTs, including 986 children, met the inclusion criteria. Pooled analysis showed no significant difference between binocular gaming and patching (SMD 0.05, 95% CI - 0.2 to 0.3, p = 0.68) with substantial heterogeneity (I<sup>2</sup> = 65%). Subgroup analyses revealed time-dependent effects: short-duration trials (≤ 6 weeks) favored binocular gaming (SMD 0.35, 95% CI 0.05-0.65, p = 0.02), medium-duration trials (8-12 weeks) showed no significant benefit, while long-duration trials (> 12 weeks) favored patching (SMD - 0.47, 95% CI - 0.72 to - 0.22, p < 0.001). Larger, high-quality trials consistently supported patching. Publication bias analysis indicated small-study effects, with trim-and-fill suggesting the true effect may favor patching (adjusted SMD - 0.15).</p><p><strong>Conclusion: </strong>Binocular gaming may provide short-term benefits, but robust evidence indicates patching is superior for long-term outcomes. After adequate refractive correction, conventional occlusion therapy remains the recommended first-line active treatment for amblyopia. Binocular gaming may be considered as an adjunct or alternative for children who are unable to comply with patching.</p><p><strong>What is known: </strong>• Patching is an effective standard treatment for childhood amblyopia. • Evidence for binocular gaming compared with patching has been inconsistent.</p><p><strong>What is new: </strong>• Binocular gaming shows short-term benefit, but patching is superior long term. • High-quality trials support patching as first-line; gaming may be an adjunct.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"73"},"PeriodicalIF":2.6,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular access in the newborn: a position paper of Neonatal European Vascular Access Teams (NEVAT). 新生儿血管通路:新生儿欧洲血管通路小组(neat)的立场文件。
IF 2.6 3区 医学 Q1 PEDIATRICS Pub Date : 2026-01-12 DOI: 10.1007/s00431-025-06717-1
Giovanni Barone, Fiammetta Piersigilli, Mauro Pittiruti

Vascular access is a cornerstone of neonatal intensive care, yet current practice remains heterogeneous due to the lack of harmonized international guidelines. In this article, we present a position paper developed by a group of European experts - the Neonatal European Vascular Access Teams (NEVAT) - designed as a guide in planning, inserting, and maintaining vascular access in neonates. The position paper was developed using a not anonymous consensus method. Seven working groups prepared preliminary drafts on seven specific topics: peripheral venous devices, umbilical catheters, epicutaneo-cava catheters, ultrasound-guided central catheters, intraosseous access, peripheral arterial catheters, and infusion line management. The drafts were analyzed, modified, and validated through multiple rounds of open discussion, until full agreement was reached. The resulting position paper advocates a proactive, individualized, and standardized approach. Key elements include evidence-based selection of the device, structured preprocedural evaluation, maximal aseptic precautions, systematic use of ultrasound, securement with cyanoacrylate and semipermeable dressings, and structured post-insertion surveillance. Infusion line management emphasizes the use of closed systems, passive disinfection caps, and checklists. The NEVAT developed this position paper with the purpose of combining best evidence with expert agreement, so as to reduce variability in clinical practice, enhance safety, and improve neonatal outcomes, while encouraging multidisciplinary collaboration and family-centered care. What is Known: • Neonates are highly vulnerable to vascular access complications, but current practice is heterogeneous, with limited evidence-based guidance and significant variability across NICUs. What is New: • The NEVAT group provides the first European position paper on neonatal vascular access, aiming to improve homogeneity in device selection, insertion, and maintenance, promoting a safer and more consistent care.

血管通路是新生儿重症监护的基石,但由于缺乏统一的国际指南,目前的实践仍然不一致。在这篇文章中,我们提出了一份由一组欧洲专家——新生儿欧洲血管通路小组(neat)——制定的立场文件,该文件旨在指导新生儿血管通路的规划、插入和维持。该立场文件是采用非匿名协商一致的方法拟订的。七个工作组准备了七个具体主题的初步草案:外周静脉装置,脐带导管,外皮腔导管,超声引导中心导管,骨内通路,外周动脉导管和输液管管理。通过多轮公开讨论,对草案进行了分析、修改和验证,直到达成完全一致。最终的立场文件提倡一种主动的、个性化的和标准化的方法。关键要素包括器械的循证选择,结构化的术前评估,最大限度的无菌预防措施,超声的系统使用,氰基丙烯酸酯和半透性敷料的安全,以及结构化的插入后监测。输液线管理强调使用封闭系统、被动消毒帽和检查清单。neat制定这一立场文件的目的是将最佳证据与专家协议相结合,从而减少临床实践中的可变性,提高安全性,改善新生儿结局,同时鼓励多学科合作和以家庭为中心的护理。•新生儿极易受到血管通路并发症的影响,但目前的实践是不一致的,基于证据的指导有限,nicu间的差异很大。新内容:•neat小组提供了欧洲第一份关于新生儿血管通路的立场文件,旨在改善器械选择、插入和维护的同质性,促进更安全、更一致的护理。
{"title":"Vascular access in the newborn: a position paper of Neonatal European Vascular Access Teams (NEVAT).","authors":"Giovanni Barone, Fiammetta Piersigilli, Mauro Pittiruti","doi":"10.1007/s00431-025-06717-1","DOIUrl":"10.1007/s00431-025-06717-1","url":null,"abstract":"<p><p>Vascular access is a cornerstone of neonatal intensive care, yet current practice remains heterogeneous due to the lack of harmonized international guidelines. In this article, we present a position paper developed by a group of European experts - the Neonatal European Vascular Access Teams (NEVAT) - designed as a guide in planning, inserting, and maintaining vascular access in neonates. The position paper was developed using a not anonymous consensus method. Seven working groups prepared preliminary drafts on seven specific topics: peripheral venous devices, umbilical catheters, epicutaneo-cava catheters, ultrasound-guided central catheters, intraosseous access, peripheral arterial catheters, and infusion line management. The drafts were analyzed, modified, and validated through multiple rounds of open discussion, until full agreement was reached. The resulting position paper advocates a proactive, individualized, and standardized approach. Key elements include evidence-based selection of the device, structured preprocedural evaluation, maximal aseptic precautions, systematic use of ultrasound, securement with cyanoacrylate and semipermeable dressings, and structured post-insertion surveillance. Infusion line management emphasizes the use of closed systems, passive disinfection caps, and checklists. The NEVAT developed this position paper with the purpose of combining best evidence with expert agreement, so as to reduce variability in clinical practice, enhance safety, and improve neonatal outcomes, while encouraging multidisciplinary collaboration and family-centered care. What is Known: • Neonates are highly vulnerable to vascular access complications, but current practice is heterogeneous, with limited evidence-based guidance and significant variability across NICUs. What is New: • The NEVAT group provides the first European position paper on neonatal vascular access, aiming to improve homogeneity in device selection, insertion, and maintenance, promoting a safer and more consistent care.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"71"},"PeriodicalIF":2.6,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of elexacaftor-tezacaftor-ivacaftor therapy on fecal elastase-1 and fat-soluble vitamins in children with cystic fibrosis. 囊性纤维化患儿粪弹性酶-1和脂溶性维生素的作用
IF 2.6 3区 医学 Q1 PEDIATRICS Pub Date : 2026-01-12 DOI: 10.1007/s00431-026-06742-8
Sanem Eryilmaz Polat, Satı Özkan Tabakçı, Işıl Bilgiç, Çelebi Yıldırım, Hande Yetişgin, Meltem Kürtül Çakar, Gamze Akça Dinç, Ayyüce Aktemur Ünlü, Şule Selin Akyan, Salih Uytun, Murat Yasin Gençoğlu, Dilber Ademhan Tural, Gökçen Dilşa Tuğcu, Güzin Cinel

Clinical studies have shown that Elexacaftor-Tezacaftor-Ivacaftor (ETI) improves lung disease and body weight in individuals with cystic fibrosis (CF); however, gastrointestinal system effects remain unclear. The purpose of this study was to evaluate exocrine pancreatic function using fecal elastase-1 (FE-1) levels in CF patients receiving ETI therapy and to assess changes in fat-soluble vitamin levels specifically within the pancreatic-insufficient (PI) subgroup. We retrospectively evaluated FE-1 levels before and during ETI treatment in the entire study group. Additionally, sweat chloride levels and growth parameters were assessed before and after follow-up ETI therapy in the entire study group. Also, vitamin A, D, E, PT, and INR levels were evaluated in PI patients before and after follow-up ETI treatment. The study included 20 pediatric CF patients with baseline FE-1 values. PI was present in 18 patients. The median age at the start of ETI therapy was 9.5 years (IQR 7.7-13.5; range 3-21 years). The median time between the baseline FE-1 test and the last FE-1 test was 12.0 months (IQR 12.0-19.5). The median FE-1 value before ETI therapy was 20.6 mcg/g (IQR 20.6-31.9), and after follow-up, 20.6 mcg/g (IQR 20.6-32.5) in 18 PI patients. Both PS patients maintained FE-1 levels ≥ 200 mcg/g before and after follow-up on ETI therapy. A significant increase in vitamin A levels was observed in PI patients, with a mean rise of 122.8 µg/L (p = 0.016). No significant change was observed in vitamin E levels (mean change 0.63 ± 4.14 µg/L; p = 0.304). Conclusion: In our study, no significant improvement in FE-1 levels was observed in pediatric CF patients receiving ETI therapy, whereas a substantial increase in vitamin A levels was found in patients with PI. These findings suggest that the effect of ETI therapy on pancreatic function may be limited and that its impact on exocrine pancreatic function should be further investigated. What is Known: • Exocrine pancreatic insufficiency is common in cystic fibrosis and is typically assessed using fecal elastase-1 (FE-1). • CFTR modulator therapies, especially ETI, improve respiratory and nutritional outcomes by targeting CFTR function, but their impact on pancreatic exocrine function in pediatric patients remains unclear. C What is New: • In this real-life pediatric cohort, no significant increase in FE-1 levels was observed during ETI treatment. • Despite improvements in CFTR function and nutritional status, these changes were not accompanied by recovery of pancreatic exocrine function.

临床研究表明,Elexacaftor-Tezacaftor-Ivacaftor (ETI)可改善囊性纤维化(CF)患者的肺部疾病和体重;然而,对胃肠道系统的影响尚不清楚。本研究的目的是利用粪便弹性酶-1 (FE-1)水平评估接受ETI治疗的CF患者的外分泌胰腺功能,并评估脂溶性维生素水平的变化,特别是在胰腺功能不足(PI)亚组中。我们回顾性地评估了整个研究组在ETI治疗前和治疗期间的FE-1水平。此外,在整个研究组随访ETI治疗前后评估汗液氯化物水平和生长参数。此外,还评估了PI患者在随访ETI治疗前后的维生素A、D、E、PT和INR水平。该研究纳入了20例基线FE-1值的儿童CF患者。18例患者出现PI。ETI治疗开始时的中位年龄为9.5岁(IQR为7.7-13.5;范围为3-21岁)。基线FE-1检查与最后一次FE-1检查之间的中位时间为12.0个月(IQR为12.0-19.5)。ETI治疗前的中位FE-1值为20.6 mcg/g (IQR 20.6-31.9),随访后18例PI患者的中位FE-1值为20.6 mcg/g (IQR 20.6-32.5)。两名PS患者在ETI治疗前后均维持FE-1水平≥200 mcg/g。在PI患者中观察到维生素A水平显著增加,平均上升122.8µg/L (p = 0.016)。维生素E水平无显著变化(平均变化0.63±4.14µg/L, p = 0.304)。结论:在我们的研究中,接受ETI治疗的儿童CF患者FE-1水平没有明显改善,而PI患者维生素a水平却有显著增加。这些发现表明,ETI治疗对胰腺功能的影响可能有限,其对外分泌胰腺功能的影响有待进一步研究。•外分泌胰腺功能不全在囊性纤维化中很常见,通常使用粪便弹性酶-1 (FE-1)进行评估。•CFTR调节疗法,特别是ETI,通过靶向CFTR功能改善呼吸和营养结果,但其对儿科患者胰腺外分泌功能的影响尚不清楚。•在这个现实生活中的儿科队列中,在ETI治疗期间未观察到FE-1水平的显着增加。•尽管CFTR功能和营养状况有所改善,但这些变化并未伴随着胰腺外分泌功能的恢复。
{"title":"Role of elexacaftor-tezacaftor-ivacaftor therapy on fecal elastase-1 and fat-soluble vitamins in children with cystic fibrosis.","authors":"Sanem Eryilmaz Polat, Satı Özkan Tabakçı, Işıl Bilgiç, Çelebi Yıldırım, Hande Yetişgin, Meltem Kürtül Çakar, Gamze Akça Dinç, Ayyüce Aktemur Ünlü, Şule Selin Akyan, Salih Uytun, Murat Yasin Gençoğlu, Dilber Ademhan Tural, Gökçen Dilşa Tuğcu, Güzin Cinel","doi":"10.1007/s00431-026-06742-8","DOIUrl":"https://doi.org/10.1007/s00431-026-06742-8","url":null,"abstract":"<p><p>Clinical studies have shown that Elexacaftor-Tezacaftor-Ivacaftor (ETI) improves lung disease and body weight in individuals with cystic fibrosis (CF); however, gastrointestinal system effects remain unclear. The purpose of this study was to evaluate exocrine pancreatic function using fecal elastase-1 (FE-1) levels in CF patients receiving ETI therapy and to assess changes in fat-soluble vitamin levels specifically within the pancreatic-insufficient (PI) subgroup. We retrospectively evaluated FE-1 levels before and during ETI treatment in the entire study group. Additionally, sweat chloride levels and growth parameters were assessed before and after follow-up ETI therapy in the entire study group. Also, vitamin A, D, E, PT, and INR levels were evaluated in PI patients before and after follow-up ETI treatment. The study included 20 pediatric CF patients with baseline FE-1 values. PI was present in 18 patients. The median age at the start of ETI therapy was 9.5 years (IQR 7.7-13.5; range 3-21 years). The median time between the baseline FE-1 test and the last FE-1 test was 12.0 months (IQR 12.0-19.5). The median FE-1 value before ETI therapy was 20.6 mcg/g (IQR 20.6-31.9), and after follow-up, 20.6 mcg/g (IQR 20.6-32.5) in 18 PI patients. Both PS patients maintained FE-1 levels ≥ 200 mcg/g before and after follow-up on ETI therapy. A significant increase in vitamin A levels was observed in PI patients, with a mean rise of 122.8 µg/L (p = 0.016). No significant change was observed in vitamin E levels (mean change 0.63 ± 4.14 µg/L; p = 0.304). Conclusion: In our study, no significant improvement in FE-1 levels was observed in pediatric CF patients receiving ETI therapy, whereas a substantial increase in vitamin A levels was found in patients with PI. These findings suggest that the effect of ETI therapy on pancreatic function may be limited and that its impact on exocrine pancreatic function should be further investigated. What is Known: • Exocrine pancreatic insufficiency is common in cystic fibrosis and is typically assessed using fecal elastase-1 (FE-1). • CFTR modulator therapies, especially ETI, improve respiratory and nutritional outcomes by targeting CFTR function, but their impact on pancreatic exocrine function in pediatric patients remains unclear. C What is New: • In this real-life pediatric cohort, no significant increase in FE-1 levels was observed during ETI treatment. • Despite improvements in CFTR function and nutritional status, these changes were not accompanied by recovery of pancreatic exocrine function.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"72"},"PeriodicalIF":2.6,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Journal of Pediatrics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1